Finance

Lists
AMPH:NASDAQ
Amphastar Pharmaceuticals, Inc
၂၉.၁၀ US$
-၀.၂၄%
(-၀.၀၇၀) 1D
၂၉.၁၀ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: နို ၁၇, GMT-၅ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMPH...
Open
၂၈.၈၇ US$
High
၂၉.၃၈ US$
Low
၂၈.၂၁ US$
Mkt. cap
၁၂၄.၁၂ ဋေ
Avg. vol.
၄.၅၈ သိန်း
Volume
၄.၁၀ သိန်း
P/E ratio
၁၃.၁၃
52-wk high
၃၀.၇၉ US$
52-wk low
၁၆.၆၄ US$
EPS
၂.၂၂ US$
Beta
၀.၉၃
Shares outstanding
၄.၂၇ ကုဋေ
No. of employees
၂ ထောင်
Open
၂၈.၈၇ US$
High
၂၉.၃၈ US$
Low
၂၈.၂၁ US$
Mkt. cap
၁၂၄.၁၂ ဋေ
Avg. vol.
၄.၅၈ သိန်း
Volume
၄.၁၀ သိန်း
P/E ratio
၁၃.၁၃
52-wk high
၃၀.၇၉ US$
52-wk low
၁၆.၆၄ US$
EPS
၂.၂၂ US$
Beta
၀.၉၃
Shares outstanding
၄.၂၇ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
Investing.com Canada
Investing.com Canada
·
ပြီးခဲ့သည့် ၁၄ နာရီ
Form 144 Amphastar Pharmaceuticals For: 17 November By Investing.com
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees၁.၉၈ ထောင်
Founded၁၉၉၆
HeadquartersRancho Cucamonga, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Analyst ratings
Based on 4 analysts giving stock ratings to AMPH in the past 3 months
Hold
Buy
0
Hold
3
Sell
1
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for AMPH in the last 3 months.
Highest
Current ၂၉.၁၀ US$
၃၀.၀၀ US$ (+၃.၀၉%)
Average
၂၅.၂၅ US$ (-၁၃.၂၃%)
Lowest
၂၃.၀၀ US$ (-၂၀.၉၆%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Sell
Reiterated
၂၃.၀၀ US$
-၂၁%
11/06/2026
Benjamin Burnett
Wells Fargo
Hold
Maintained
၂၅.၀၀ US$
-၁၄.၁%
11/06/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
၃၀.၀၀ US$
+၃.၁%
10/22/2026
Glen Santangelo
Barclays
Hold
Maintained
၂၃.၀၀ US$
-၂၁%
08/18/2026
Serge Belanger
Needham
Hold
Maintained
၂၀.၀၀ US$
-၃၁.၃%
08/07/2026
David Amsellem
Piper Sandler
Hold
Reiterated
၂၀.၀၀ US$
-၃၁.၃%
08/07/2026
Chi Meng Fong
Bank of America Securities
Hold
Reiterated
၂၅.၀၀ US$
-၁၄.၁%
05/07/2026
Dennis Ding
Jefferies
Hold
Downgraded
၂၂.၀၀ US$
-၂၄.၄%
04/21/2026
Cerena Chen
Wells Fargo
Buy
Maintained
၃၀.၀၀ US$
+၃.၁%
02/27/2026
Pavan Patel
Bank of America Securities
Hold
Reiterated
၂၈.၀၀ US$
-၃.၈%
02/26/2026
Last report
၂၀၂၆ နို ၆
Fiscal period
Q3 2026
၁.၁၄ US$ / ၀.၈၆ US$
+၃၂.၇၆%beat
Revenue / Est. (USD)
၂၀.၇၆ ကုဋေ / ၁၉.၇၅ ကုဋေ
+၅.၁၂%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
၁၈.၃၁ ကုဋေ
၁၇.၁၂ ကုဋေ
၁၈.၃၉ ကုဋေ
၂၀.၇၆ ကုဋေ
Cost of goods sold
၉.၇၄ ကုဋေ
၁၀.၀၈ ကုဋေ
၉.၀၄ ကုဋေ
၁၀.၈၀ ကုဋေ
Cost of revenue
၉.၇၄ ကုဋေ
၁၀.၀၈ ကုဋေ
၉.၀၄ ကုဋေ
၁၀.၈၀ ကုဋေ
Research and development expenses
၂.၃၃ ကုဋေ
၂.၆၇ ကုဋေ
၂.၂၂ ကုဋေ
၂.၀၁ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂.၆၈ ကုဋေ
၃.၀၀ ကုဋေ
၃.၁၆ ကုဋေ
၂.၈၈ ကုဋေ
Operating expense
၅.၀၁ ကုဋေ
၅.၆၇ ကုဋေ
၅.၃၇ ကုဋေ
၄.၈၉ ကုဋေ
Total operating expenses
၁၄.၇၅ ကုဋေ
၁၅.၇၅ ကုဋေ
၁၄.၄၂ ကုဋေ
၁၅.၆၈ ကုဋေ
Operating income
၃.၅၆ ကုဋေ
၁.၃၆ ကုဋေ
၃.၉၇ ကုဋေ
၅.၀၈ ကုဋေ
Other non operating income
၂.၁၅ သိန်း
-၁.၄၂ သန်း
၁.၂၉ သန်း
-၂.၃၆ သိန်း
EBT including unusual items
၃.၁၉ ကုဋေ
၁.၀၁ ကုဋေ
၃.၈၅ ကုဋေ
၄.၉၁ ကုဋေ
EBT excluding unusual items
၃.၁၉ ကုဋေ
၁.၀၁ ကုဋေ
၃.၈၅ ကုဋေ
၄.၉၁ ကုဋေ
Income tax expense
၇.၄၈ သန်း
၃.၆၃ သန်း
၈.၂၀ သန်း
၁.၁၃ ကုဋေ
Effective tax rate
၂၃.၄၅%
၃၆.၁၃%
၂၁.၂၆%
၂၃.၀၃%
Other operating expenses
-
-
-
-
Net income
၂.၄၄ ကုဋေ
၆.၄၂ သန်း
၃.၀၃ ကုဋေ
၃.၇၈ ကုဋေ
Net profit margin
၁၃.၃၄%
၃.၇၅%
၁၆.၅၀%
၁၈.၁၉%
Earnings per share
၀.၇၃
၀.၄၂
၀.၉၁
၁.၁၄
Interest and investment income
၂.၄၂ သန်း
၂.၄၀ သန်း
၂.၂၉ သန်း
၂.၂၉ သန်း
Interest expense
-၆.၃၃ သန်း
-၄.၅၅ သန်း
-၄.၅၆ သန်း
-၃.၇၆ သန်း
Net interest expenses
-၃.၉၁ သန်း
-၂.၁၅ သန်း
-၂.၂၇ သန်း
-၁.၄၇ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
၄.၉၉ ကုဋေ
၂.၈၀ ကုဋေ
၅.၄၀ ကုဋေ
၆.၆၄ ကုဋေ
Gain or loss from assets sale
၆.၀၀ ထောင်
၄.၀၀ ထောင်
၉.၀၀ ထောင်
၄.၂၃ သိန်း
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ